US Patent 4,695,576: Levobupivacaine Claims, Expiration, and Patent Landscape

US Patent 4,695,576 covers the substantially pure L-isomer of bupivacaine, now known as levobupivacaine, and its water-soluble salts. The patent claims the compound, injectable aqueous solutions, topical compositions, and methods of inducing local anesthesia. Its enforceable term expired in 2004, so the patent no longer blocks generic manufacture, formulation, or use of levobupivacaine in the United States.[1]

What drug does US Patent 4,695,576 protect?

The patent protects the L-isomer of N-n-propylpipecolic acid-2,6-xylidide. This chemical is levobupivacaine, commonly marketed as levobupivacaine hydrochloride.

Bupivacaine has a chiral center and exists as:

The L-isomer, levobupivacaine
The D-isomer, dextrobupivacaine
The racemic mixture, bupivacaine

The patent distinguishes levobupivacaine from racemic bupivacaine and the D-isomer. Its central technical proposition is that the substantially pure L-isomer provides local anesthetic activity while offering a different toxicity profile from the racemate.

The covered pharmaceutical forms include the free compound and water-soluble salts, particularly salts suitable for aqueous injection. Levobupivacaine hydrochloride is the commercially relevant form.

What is the patent’s central inventive concept?

The patent’s central concept is the isolation and use of substantially pure levobupivacaine rather than racemic bupivacaine. The claims are directed to both:

The chemical entity itself and its salts.
Its use in local anesthesia.

The patent therefore combines composition-of-matter protection with method-of-use and dosage-form coverage.

What are the claims of US Patent 4,695,576?

The six claims divide into four practical categories.

Claim	Claim type	Covered subject matter
1	Method of use	Administration of substantially pure L-isomer or water-soluble salts for local anesthesia
2	Method plus formulation	Claim 1 where the compound is in an injectable aqueous solution
3	Composition of matter	Substantially pure L-isomer and water-soluble salts substantially free of racemate and D-isomer
4	Human method of use	Application to the intended anesthetic region at an effective, non-toxic concentration
5	Injectable composition	Aqueous solution containing a water-soluble salt for human local anesthesia
6	Topical composition	A carrier containing the compound of claim 3

How broad is claim 3?

Claim 3 is the strongest claim from a patent-law perspective because it claims the substantially pure L-isomer itself, rather than only a particular use.

The claim covers:

Levobupivacaine in substantially pure form
Water-soluble salts of levobupivacaine
Products substantially devoid of racemic bupivacaine
Products substantially devoid of the D-isomer

A product containing levobupivacaine hydrochloride would fall within the technical subject matter of claim 3 if it satisfied the patent’s purity and stereochemical limitations. The claim is not limited to a particular concentration, injection volume, preservative, pH, container, or dosage strength.

The purity language is important. “Substantially pure” and “substantially devoid” require interpretation in light of the patent specification, analytical methods, and the level of stereochemical contamination tolerated by the claim. The claim does not state a numerical enantiomeric-purity threshold on its face.

How broad are claims 1, 2, 4, 5, and 6?

Claim 1 covers administration of the L-isomer or its water-soluble salts to a patient requiring local anesthesia. It is not limited to a specific anatomical procedure, route, concentration, or dose, except that the amount must be anesthetizing.

Claim 2 narrows claim 1 to an injectable aqueous solution.

Claim 4 is a human-use claim. It covers applying the claimed compound to the region intended to be anesthetized at a concentration that is effective but below the level producing an adverse toxic reaction.

Claim 5 covers an injectable aqueous composition containing a water-soluble salt. It is narrower than claim 3 because it requires:

An aqueous solution
An injectable composition
A local-anesthetic amount
Human use
A non-toxic concentration

Claim 6 covers a topical composition containing a carrier and the claimed compound. It does not require an aqueous formulation or injection.

What formulations are protected by US Patent 4,695,576?

The patent reaches two principal dosage-form categories.

Injectable levobupivacaine formulations

Claims 2 and 5 cover injectable aqueous solutions, including solutions containing a water-soluble salt such as levobupivacaine hydrochloride. The claims do not require a specific:

Concentration
Buffer system
Preservative
Osmolality
Container
Injection route
Commercial presentation

An injectable product could therefore fall within the claims based on the active ingredient and general aqueous-composition characteristics, without duplicating a branded formulation.

Topical levobupivacaine formulations

Claim 6 covers a topical composition containing a carrier and levobupivacaine. The carrier could include a cream, gel, ointment, lotion, or other topical vehicle, provided the formulation satisfies the claim language.

The topical claim is not restricted to a particular excipient system. It is broader than a formulation claim limited to a named vehicle or concentration, but it still depends on the presence of the claimed stereochemically pure compound.

When did US Patent 4,695,576 expire?

US Patent 4,695,576 was issued on September 22, 1987. Because it was an older US patent subject to the pre-URAA patent-term rule, its term was generally 17 years from issuance. The patent therefore expired on September 22, 2004, absent an unusual term adjustment or enforceable extension.[1][2]

The practical result is:

Event	Date or status
US patent grant	September 22, 1987
Standard patent term	17 years from grant
Expiration	September 22, 2004
Current enforceability	Expired
Current blocking effect on generic entry	None from this patent

Patent term restoration under 35 U.S.C. § 156 was generally unavailable for this patent as a practical matter because the relevant commercial approval occurred after the ordinary patent term had already ended. The patent cannot now be asserted to prevent manufacture, sale, or use of levobupivacaine in the United States.

What is the Orange Book status of levobupivacaine?

Levobupivacaine hydrochloride was approved by the FDA under the Chirocaine brand through NDA 020533. The product received US approval in 1999 for local and regional anesthesia.[3]

The relevant regulatory distinction is between:

FDA approval of the drug product
Orange Book listing of patents
Enforceability of a listed patent
Regulatory exclusivity

US Patent 4,695,576 is expired and cannot impose a current Orange Book patent barrier. Any historical Orange Book listing would not create a present-day patent block.

Levobupivacaine is a small-molecule drug. It is not subject to the biosimilar pathway under the Biologics Price Competition and Innovation Act. A follow-on applicant would pursue an abbreviated new drug application, where applicable, or another small-molecule FDA pathway rather than a biosimilar application.[4]

What Paragraph IV risks applied to levobupivacaine?

A Paragraph IV certification could historically have been relevant if an abbreviated new drug applicant challenged an unexpired listed patent covering levobupivacaine or its approved uses. US Patent 4,695,576 is no longer relevant to that analysis because it expired in 2004.

The patent’s original claim structure would have created several potential Paragraph IV theories:

Non-infringement based on a product not meeting the “substantially pure” limitation
Invalidity based on anticipation or obviousness
Invalidity or non-infringement based on the scope of “substantially devoid”
Non-infringement for a formulation outside the injectable or topical limitations
Lack of infringement for uses outside local anesthesia

Those theories no longer have commercial significance against this patent because expiration removes the need to defeat the patent. A current applicant would focus on any later, unexpired patents listed for the specific reference product.

Which companies challenged the patent?

The patent record itself does not establish a current Paragraph IV challenger because the patent expired before modern levobupivacaine generic competition became commercially important. No current company can be required to defeat US Patent 4,695,576 as a condition of entry.

The commercial reference product was Chirocaine, associated in the United States with Abbott Laboratories. Later generic manufacturers could enter without licensing this patent because its term had ended.

The absence of a current challenge does not eliminate the need to review later patents covering:

Specific concentrations
Preservative-free products
Container systems
Premixed solutions
Manufacturing processes
Combination products
Narrower therapeutic uses

Those later rights would be separate from US Patent 4,695,576.

How strong was the patent estate for levobupivacaine?

The original patent was strong in scope because claim 3 was directed to the active stereoisomer itself. A valid composition-of-matter claim generally provides broader protection than a claim limited to one formulation or indication.

Its principal strengths were:

Coverage of the active L-isomer
Coverage of water-soluble salts
Coverage independent of a particular dosage form
Separate method-of-use claims
Separate injectable and topical composition claims
Exclusion of racemic and D-isomer material

Its principal limitations were:

Dependence on stereochemical purity
Potential factual disputes over “substantially pure” and “substantially devoid”
Functional limitations requiring local anesthesia
Formulation restrictions in claims 2 and 5
Topical-carrier requirement in claim 6
Limited geographic scope as a US patent
Complete expiration in 2004

As an active patent, claim 3 would have been the primary commercial barrier. As an expired patent, the entire estate now has historical rather than blocking value.

How does levobupivacaine compare with racemic bupivacaine?

Issue	Levobupivacaine	Racemic bupivacaine
Stereochemistry	Predominantly L-isomer	Mixture of L- and D-isomers
US Patent 4,695,576	Directly targeted	Expressly excluded from the claimed pure L-isomer
Primary product form	Levobupivacaine hydrochloride	Bupivacaine hydrochloride
FDA regulatory category	Small molecule	Small molecule
Biosimilar exposure	None	None
Patent status under 4,695,576	Expired	Not covered as the claimed racemate
Commercial rationale	Chiral product with differentiated safety profile	Established long-acting local anesthetic

The patent did not claim all bupivacaine products. It specifically distinguished the L-isomer from racemic and D-isomer material. A racemic bupivacaine product would not infringe claim 3 merely because it contains the L-isomer, assuming the claim’s exclusion and purity limitations are not met.

What manufacturing and IP barriers remain?

US Patent 4,695,576 no longer creates a manufacturing barrier. The historic technical barrier was the ability to:

Resolve or synthesize the desired enantiomer
Maintain high stereochemical purity
Produce a pharmaceutically acceptable salt
Formulate the salt in an injectable aqueous product
Control impurities and degradation products
Demonstrate equivalent quality and stability

Current commercial barriers are more likely to arise from regulatory compliance, sterile manufacturing, supply reliability, and any later patents covering specific products or processes. These issues are distinct from the expired composition-of-matter patent.

What is the geographic coverage of the patent?

US Patent 4,695,576 has US territorial effect only. It could not directly block manufacture, sale, or use outside the United States.

Foreign counterpart patents, if granted, would have had separate filing dates, claim scope, term calculations, and expiration dates. The US expiration date cannot automatically be applied to foreign family members. Any surviving foreign rights would require country-by-country review of the relevant patent family and national-phase records.

What is the commercial exposure from the patent?

The patent likely provided the central historical exclusivity position for levobupivacaine in the United States before and around the 1999 Chirocaine launch. Its expiration in 2004 removed the principal product-level patent barrier.

Current revenue exposure is therefore determined by:

Brand retention
Generic price erosion
Hospital contracting
Surgical and regional-anesthesia demand
Formulation differentiation
Distribution economics
Later patents and regulatory exclusivities

US Patent 4,695,576 itself does not support a current royalty claim or litigation-based revenue forecast.

Key Takeaways

US Patent 4,695,576 covers substantially pure levobupivacaine, the L-isomer of bupivacaine.
Claim 3 is the broadest and most commercially important claim because it covers the compound and its water-soluble salts.
Claims 1, 2, 4, 5, and 6 cover local-anesthetic use, injectable aqueous solutions, human administration, and topical compositions.
The patent issued on September 22, 1987, and expired on September 22, 2004.
The patent is not a current barrier to generic levobupivacaine entry in the United States.
Levobupivacaine is a small molecule and has no biosimilar pathway.
Any current patent risk must come from later patents, not US Patent 4,695,576.
The patent’s historical strength came from composition-of-matter protection for the enantiopure active ingredient.

FAQs About US Patent 4,695,576 and Levobupivacaine

Does US Patent 4,695,576 cover bupivacaine?

No. It primarily covers substantially pure levobupivacaine and its water-soluble salts. The claims expressly distinguish the L-isomer from racemic bupivacaine and the D-isomer.

Is levobupivacaine protected by an active US composition patent?

US Patent 4,695,576 is expired. It therefore does not provide active US composition-of-matter protection.

Can a generic company manufacture levobupivacaine without a license to this patent?

Yes. The patent expired in 2004, so a license to US Patent 4,695,576 is not required for US manufacture or sale.

Did the patent cover topical levobupivacaine?

Yes. Claim 6 covers a topical local-anesthetic composition containing a carrier and the substantially pure L-isomer or its covered salts.

Does levobupivacaine require a Paragraph IV certification today?

Not to US Patent 4,695,576. A Paragraph IV certification would be relevant only to an unexpired patent listed for the applicable reference product.

References

United States Patent and Trademark Office. (1987). US Patent No. 4,695,576.
United States Code, 35 U.S.C. § 154. Patent term provisions.
U.S. Food and Drug Administration. (1999). Drugs@FDA: Chirocaine (levobupivacaine hydrochloride), NDA 020533.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

Details for Patent: 4,695,576

Summary for Patent: 4,695,576